Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$76,731.00-2.97%ETH$2,237.33-1.61%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
A

NYSE · A

Agilent Technologies, Inc.

Healthcare · Medical - Diagnostics & Research

$181.15

Down-$6.28 (-3.47%)

Updated Oct 30, 2026, 9:52 PM

SID Score

7.8/10

Composite research score

Smart Money

54/100

Neutral

Market cap
34.41B
P/E ratio
26.63
Dividend yield
0.69%
52-week range
$108.35 – $182.99
Volume
1.82M
Avg. volume
2.17M

Price performance · A

A price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 29, 2026

A closed at $181.15 after 21 trading sessions, up 8.68% for the selected period.

Last close
$181.15
Period change
+8.68%
Period low
$166.68
Period high
$181.48
Daily close
View OHLC price history
A OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 29, 2026$182.00$182.72$179.65$181.151.82M
Oct 28, 2026$177.18$182.99$176.77$181.481.55M
Oct 27, 2026$175.24$179.10$174.03$177.492.29M
Oct 26, 2026$174.40$176.79$174.0736$175.961.71M
Oct 23, 2026$173.16$173.59$169.89$173.071.76M
Oct 22, 2026$177.50$179.10$171.23$173.892.65M
Oct 21, 2026$170.73$178.21$170.73$177.752.14M
Oct 20, 2026$170.94$174.80$170.375$173.011.98M
Oct 19, 2026$173.82$175.00$169.59$169.902.47M
Oct 16, 2026$175.04$177.47$172.16$172.972.9M
Oct 15, 2026$175.00$177.04$173.69$175.551.89M
Oct 14, 2026$172.19$175.54$171.67$174.002.37M
Oct 13, 2026$171.87$172.74$169.895$171.601.54M
Oct 12, 2026$171.41$171.89$170.04$171.331.51M
Oct 9, 2026$168.57$172.19$168.57$170.541.54M
Oct 8, 2026$167.48$168.66$163.32$168.172.72M
Oct 7, 2026$169.88$171.27$166.52$169.092.56M
Oct 6, 2026$172.77$176.38$168.01$169.331.87M
Oct 5, 2026$167.35$171.425$166.49$171.291.77M
Oct 2, 2026$168.25$170.24$166.33$167.782.29M
Oct 1, 2026$172.00$172.57$166.07$166.682.79M

Latest A news

The latest Smart Investors Daily articles mentioning A.

Stock researchCompany · Overview

A research

Overview

Company profile and research snapshot.

Company profile

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$165.56
Implied upside
—
Analysts
26
A recent ratings
DateFirmRatingTarget
Oct 26, 2026Deutsche BankBuy—
Oct 13, 2026Morgan StanleyOverweight—
Oct 13, 2026TD CowenBuy—
Oct 7, 2026BarclaysOverweight—
Aug 27, 2026BernsteinOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 21, 2026

Bioconjugation Market Report 2026: Global Size, Share, Trends and 2030 Forecast | Capitalize on Targeted Therapeutics | Thermo Fisher, Merck, Danaher, Lonza, and Agilent Lead the Industry

Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- "Bioconjugation Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global bioconjugation market is experiencing rapid growth, supported by expanding biologics research, increased development of antibody-based therapeutics, and rising demand for advanced diagnostic assays. The market is projected to grow from $6.12 billion in 2025 to $6.89 billion in 2026, representing a compound annual growth rate (CAGR) of 12.5%. Growth during

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By